GlaxoSmithKline's BCMA ADC Phase II trial yields positive results

On March 7th, GlaxoSmithKline (GSK) announced positive interim analysis results from the Phase III head-to-head trial (DREAMM-7), which evaluated the efficacy of Blenrep (belantamab mafodotin) in combination with pomalidomide and dexamethasone (PomDex) versus standard treatment of bortezomib plus PomDex as second-line and later treatment for relapsed or refractory multiple myeloma (R/R MM). In the pre-specified interim analysis, the trial met its primary endpoint of progression-free survival (PFS). Blenrep in combination therapy significantly prolonged the time to disease progression or death compared to standard treatment. This analysis also observed a positive trend favoring Blenrep combination therapy for overall survival (OS). The trial will continue to follow up. The safety and tolerability of the Blenrep regimen were generally consistent with the known safety profiles of individual drugs. This study represents the second head-to-head Phase III trial of Blenrep for second-line and later treatment of MM. Previously, the Phase III DREAMM-7 study of Blenrep for second-line treatment of R/R MM also yielded positive interim results. Additionally, compared to daratumumab in combination with BorDex (bortezomib + dexamethasone), Blenrep in combination with BorDex significantly extended the time to disease progression or death for patients."